Lisa Jörimann

Sustained Viral Suppression With Dolutegravir Monotherapy Over 192 Weeks in Patients Starting Combination Antiretroviral Therapy During Primary Human Immunodeficiency Virus Infection (EARLY-SIMPLIFIED): A Randomized, Controlled, Multi-site, Noninferiority Trial

Emily West, Marius Zeeb, Christina Grube et al. · Clinical Infectious Diseases · 2023 · 13 citations · Full text

Spontaneous reactivation of latent HIV-1 promoters is linked to the cell cycle as revealed by a genetic-insulators-containing dual-fluorescence HIV-1-based vector

Yik Lim Kok, Stefan Schmutz, Anne Inderbitzin et al. · Scientific Reports · 2018 · 12 citations · Full text

Prevalence of HIV-1 drug resistance mutations in proviral DNA in the Swiss HIV Cohort Study, a retrospective study from 1995 to 2018

Bashkim Jaha, Corinne D Schenkel, Lisa Jörimann et al. · Journal of Antimicrobial Chemotherapy · 2023 · 11 citations · Full text

Absence of Proviral Human Immunodeficiency Virus (HIV) Type 1 Evolution in Early-Treated Individuals With HIV Switching to Dolutegravir Monotherapy During 48 Weeks

Lisa Jörimann, Jasmin Tschumi, Marius Zeeb et al. · The Journal of Infectious Diseases · 2023 · 10 citations · Full text